Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company PLx Pharma Inc.
DescriptionFormulation of 5-ASA using PLxGuard technology
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPreclinical
Standard IndicationInflammatory bowel disease (IBD)
Indication DetailsTreat inflammatory bowel disease (IBD)
Regulatory Designation
PartnerCambrex Corp.;
Zeria Pharmaceutical Co. Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today